Healthcare
Visualizing the History of Pandemics
Published
6 years agoon
Article/Editing:
Graphics/Design:

Can I share this graphic?Yes. Visualizations are free to share and post in their original form across the web—even for publishers. Please link back to this page and attribute Visual Capitalist.
When do I need a license?Licenses are required for some commercial uses, translations, or layout modifications. You can even whitelabel our visualizations. Explore your options.
Interested in this piece?Click here to license this visualization.
The History of Pandemics
Pan·dem·ic /panˈdemik/ (of a disease) prevalent over a whole country or the world.
As humans have spread across the world, so have infectious diseases. Even in this modern era, outbreaks are nearly constant, though not every outbreak reaches pandemic level as COVID-19 has.
Today’s visualization outlines some of history’s most deadly pandemics, from the Antonine Plague to the current COVID-19 event.
A Timeline of Historical Pandemics
Disease and illnesses have plagued humanity since the earliest days, our mortal flaw. However, it was not until the marked shift to agrarian communities that the scale and spread of these diseases increased dramatically.
Widespread trade created new opportunities for human and animal interactions that sped up such epidemics. Malaria, tuberculosis, leprosy, influenza, smallpox, and others first appeared during these early years.
The more civilized humans became – with larger cities, more exotic trade routes, and increased contact with different populations of people, animals, and ecosystems – the more likely pandemics would occur.
Here are some of the major pandemics that have occurred over time:
| Name | Time period | Type / Pre-human host | Death toll |
|---|---|---|---|
| Antonine Plague | 165-180 | Believed to be either smallpox or measles | 5M |
| Japanese smallpox epidemic | 735-737 | Variola major virus | 1M |
| Plague of Justinian | 541-542 | Yersinia pestis bacteria / Rats, fleas | 30-50M |
| Black Death | 1347-1351 | Yersinia pestis bacteria / Rats, fleas | 200M |
| New World Smallpox Outbreak | 1520 – onwards | Variola major virus | 56M |
| Great Plague of London | 1665 | Yersinia pestis bacteria / Rats, fleas | 100,000 |
| Italian plague | 1629-1631 | Yersinia pestis bacteria / Rats, fleas | 1M |
| Cholera Pandemics 1-6 | 1817-1923 | V. cholerae bacteria | 1M+ |
| Third Plague | 1885 | Yersinia pestis bacteria / Rats, fleas | 12M (China and India) |
| Yellow Fever | Late 1800s | Virus / Mosquitoes | 100,000-150,000 (U.S.) |
| Russian Flu | 1889-1890 | Believed to be H2N2 (avian origin) | 1M |
| Spanish Flu | 1918-1919 | H1N1 virus / Pigs | 40-50M |
| Asian Flu | 1957-1958 | H2N2 virus | 1.1M |
| Hong Kong Flu | 1968-1970 | H3N2 virus | 1M |
| HIV/AIDS | 1981-present | Virus / Chimpanzees | 25-35M |
| Swine Flu | 2009-2010 | H1N1 virus / Pigs | 200,000 |
| SARS | 2002-2003 | Coronavirus / Bats, Civets | 770 |
| Ebola | 2014-2016 | Ebolavirus / Wild animals | 11,000 |
| MERS | 2015-Present | Coronavirus / Bats, camels | 850 |
| COVID-19 | 2019-Present | Coronavirus – Unknown (possibly pangolins) | 6.9M (Johns Hopkins University estimate as of March 1, 2023) |
Note: Many of the death toll numbers listed above are best estimates based on available research. Some, such as the Plague of Justinian and Swine Flu, are subject to debate based on new evidence.
Despite the persistence of disease and pandemics throughout history, there’s one consistent trend over time – a gradual reduction in the death rate. Healthcare improvements and understanding the factors that incubate pandemics have been powerful tools in mitigating their impact.
March 1, 2023 Update: Due to popular request, we’ve also visualized how the death tolls of each pandemic stack up as a share of total estimated global populations at the time.

Wrath of the Gods
In many ancient societies, people believed that spirits and gods inflicted disease and destruction upon those that deserved their wrath. This unscientific perception often led to disastrous responses that resulted in the deaths of thousands, if not millions.
In the case of Justinian’s plague, the Byzantine historian Procopius of Caesarea traced the origins of the plague (the Yersinia pestis bacteria) to China and northeast India, via land and sea trade routes to Egypt where it entered the Byzantine Empire through Mediterranean ports.
Despite his apparent knowledge of the role geography and trade played in this spread, Procopius laid blame for the outbreak on the Emperor Justinian, declaring him to be either a devil, or invoking God’s punishment for his evil ways. Some historians found that this event could have dashed Emperor Justinian’s efforts to reunite the Western and Eastern remnants of the Roman Empire, and marked the beginning of the Dark Ages.
Luckily, humanity’s understanding of the causes of disease has improved, and this is resulting in a drastic improvement in the response to modern pandemics, albeit slow and incomplete.
Importing Disease
The practice of quarantine began during the 14th century, in an effort to protect coastal cities from plague epidemics. Cautious port authorities required ships arriving in Venice from infected ports to sit at anchor for 40 days before landing — the origin of the word quarantine from the Italian “quaranta giorni”, or 40 days.
One of the first instances of relying on geography and statistical analysis was in mid-19th century London, during a cholera outbreak. In 1854, Dr. John Snow came to the conclusion that cholera was spreading via tainted water and decided to display neighborhood mortality data directly on a map. This method revealed a cluster of cases around a specific pump from which people were drawing their water from.
While the interactions created through trade and urban life play a pivotal role, it is also the virulent nature of particular diseases that indicate the trajectory of a pandemic.
Tracking Infectiousness
Scientists use a basic measure to track the infectiousness of a disease called the reproduction number — also known as R0 or “R naught.” This number tells us how many susceptible people, on average, each sick person will in turn infect.

Measles tops the list, being the most contagious with a R0 range of 12-18. This means a single person can infect, on average, 12 to 18 people in an unvaccinated population.
While measles may be the most virulent, vaccination efforts and herd immunity can curb its spread. The more people are immune to a disease, the less likely it is to proliferate, making vaccinations critical to prevent the resurgence of known and treatable diseases.
It’s hard to calculate and forecast the true impact of COVID-19, as the outbreak is still ongoing and researchers are still learning about this new form of coronavirus.
Urbanization and the Spread of Disease
We arrive at where we began, with rising global connections and interactions as a driving force behind pandemics. From small hunting and gathering tribes to the metropolis, humanity’s reliance on one another has also sparked opportunities for disease to spread.
Urbanization in the developing world is bringing more and more rural residents into denser neighborhoods, while population increases are putting greater pressure on the environment. At the same time, passenger air traffic nearly doubled in the past decade. These macro trends are having a profound impact on the spread of infectious disease.
As organizations and governments around the world ask for citizens to practice social distancing to help reduce the rate of infection, the digital world is allowing people to maintain connections and commerce like never before.
Editor’s Note: The COVID-19 pandemic is in its early stages and it is obviously impossible to predict its future impact. This post and infographic are meant to provide historical context, and we will continue to update it as time goes on to maintain its accuracy.
Update (March 1, 2023): We’ve adjusted the death toll for COVID-19, and will continue to update on a regular basis.
You may also like
-
Ranked: The World’s Oldest People in History
-
Europe’s Top Causes of Death, Ranked—Cancer Is #2
-
Animated Chart: America’s Top Names for Girls, by Decade (1880-Today)
-
History’s Biggest Companies vs. The Magnificent Seven
-
Charted: The Rise of Stock Market Volatility (2017-2025)
-
Ranked: The 40 Countries With the Best Culture and Heritage
Healthcare
Ranked: America’s Most Expensive Drugs
America’s most expensive drugs now top $4 million per dose. See why gene therapies carry record-breaking price tags.
Published
5 days agoon
October 30, 2025By
Pallavi Rao
Ranked: America’s Most Expensive Drugs
This was originally posted on our Voronoi app. Download the app for free on iOS or Android and discover incredible data-driven charts from a variety of trusted sources.
Key Takeaways
- Lenmeldy is America’s priciest drug in 2025 at $4.25 million per dose.
- One Lenmeldy treatment equals roughly 12,500 Ozempic doses ($342 each, before insurance)
In 2025, the soaring cost of cutting-edge gene therapies has pushed individual drug prices to record highs.
The latest ranking of America’s most expensive drugs highlights how a single treatment can rival the price of a luxury home.
The data for this visualization comes from Fierce Pharma. It lists the 10 priciest U.S. drugs, all topping $2 million per course and most offering one-time, potentially curative benefits
Gene Therapies Dominate the Leaderboard
Lenmeldy, a treatment for the ultrarare disorder metachromatic leukodystrophy, costs $4.25 million per dose, eclipsing every other therapy launched to date.
| Rank | Drug Name | Cost Per Dose | Company | Used For |
|---|---|---|---|---|
| 1 | Lenmeldy | $4,250,000 | Kyowa Kirin | A gene therapy used to treat kids with metachromatic leukodystrophy (MLD), a rare inherited metabolic disorder |
| 2 | Kebilidi | $3,950,000 | PTC Therapeutics | A gene therapy used to treat children & adults with AADC deficiency, a rare disorder that prevents the body from making key brain chemicals |
| 3 | Hemgenix | $3,500,000 | CSL Behring | A one-time gene therapy used to treat adults with hemophilia B to reduce bleeding episodes |
| 4 | Elevidys | $3,200,000 | Sarepta Therapeutics | A gene therapy used to treat Duchenne muscular dystrophy (DMD) in people 4 years and older |
| 5 | Lyfgenia | $3,100,000 | bluebird bio | A one-time gene therapy used to treat sickle cell disease with a history of pain crises |
| 6 | Skysona | $3,000,000 | bluebird bio | A gene therapy used to slow nerve damage in boys with early, active cerebral adrenoleukodystrophy (CALD) |
| 7 | Roctavian | $2,900,000 | BioMarin | A one-time gene therapy used to treat adults with severe hemophilia A who don’t have AAV5 antibodies |
| 8 | Rethymic | $2,810,000 | Sumitomo Pharma | A tissue-based therapy used to help kids with congenital athymia build a working immune system |
| 9 | Zynteglo | $2,800,000 | bluebird bio | A gene therapy used to treat people with transfusion dependent beta thalassemia |
| 10 | Zolgensma | $2,320,000 | Novartis | A one-time gene therapy used to treat children under 2 with spinal muscular atrophy (SMA) |
Note: Bluebird Bio is now Genetix Biotherapeutics after acquisition by two private equity firms.
Lenmeldy’s list price equals roughly 12,500 doses of popular diabetes drug Ozempic at its pre-insurance list price.
While the number seems astronomical, payers weigh it against lifelong care costs that can exceed $10 million for untreated MLD patients.
Similarly, third-ranked Hemgenix’s one-time $3.5 million cost compares with up to $20 million for decades of clotting-factor infusions.
Even at multimillion-dollar stickers, pay-once gene therapies can offer health-economic value over chronic treatments.
In fact, every drug on the top 10 list is a gene or cell-based therapy—scientific breakthroughs that replace or repair faulty genetic instructions.
Because they aim to cure rare and deadly conditions in a single dose, their development and manufacturing pipelines are complex, bespoke, and expensive.
Bluebird Bio’s Three-Drug Footprint
No company appears more often than Bluebird Bio, which places Lyfgenia, Skysona, and Zynteglo on the list.
Each addresses a different inherited blood or metabolic disorder, yet all share core technology roots developed over a decade.
Despite regulatory scrutiny and manufacturing setbacks, the company’s persistence has translated into multiple FDA approvals.
The cluster illustrates how a single firm can dominate a high-value therapeutic niche.
Bluebird Bio was acquired in June, 2025 by private equity firms Carlyle Group and SK Capital.
Learn More on the Voronoi App 
For related coverage, check out Where Americans Pay the Most (and Least) for Health Insurance on Voronoi, the new app from Visual Capitalist.
Business
Ranked: America’s Most Common Drugs by Medicare Spending
Looking at what’s shaping U.S. healthcare trends by sifting through data about America’s most common drugs by Medicare spending, who manufactures them, and how much they cost.
Published
2 weeks agoon
October 21, 2025By
Pallavi Rao
Ranked: America’s Most Common Drugs by Medicare Spending
This was originally posted on our Voronoi app. Download the app for free on iOS or Android and discover incredible data-driven charts from a variety of trusted sources.
Key Takeaways
- Eliquis tops 2023 Medicare spending at $18.3 billion, more than twice the second-ranked drug (Ozempic).
- An aging population—and related conditions like blood clots—are reshaping U.S. healthcare costs.
- The top 35 drugs by Medicare spending are produced by just 20 companies, highlighting the market’s concentration and pricing power.
From diabetes injectables to blockbuster blood thinners, a handful of drugs account for a sizable share of Medicare’s pharmacy bill.
This visualization ranks the most common drugs by total Medicare spending in 2023, sourced from Centers for Medicare & Medicaid Services
It tracks every claim, dosage, and dollar flowing through Medicare Part D, the federal prescription-drug benefit.
Blood Thinners Are America’s Most Common Drug
Eliquis (generic name: Apixaban) alone racked up $18.3 billion in Medicare spending in 2023, nearly double the next drug, Ozempic.
Alongside Xarelto, anticoagulants accounted for over $24 billion in 2023.
| Rank | Drug Name | Company | Total Medicare Spending (2023) | Prevents / Treats |
|---|---|---|---|---|
| 1 | Eliquis | BMS Primarycare | $18,273,451,967 | Blood clots |
| 2 | Ozempic | Novo Nordisk | $9,194,048,435 | Diabetes, weight loss |
| 3 | Jardiance | Boehringer Ing. | $8,839,935,063 | Diabetes |
| 4 | Trulicity | Eli Lilly & Co. | $7,363,856,224 | Diabetes |
| 5 | Xarelto | Janssen Pharm. | $6,309,246,823 | Blood clots |
| 6 | Trelegy Ellipta | Glaxosmithkline | $4,455,884,010 | COPD |
| 7 | Humira(Cf) Pen | Abbvie US LLC | $4,419,828,188 | Arthritis, Crohn's disease |
| 8 | Farxiga | Astrazeneca | $4,342,182,307 | Diabetes |
| 9 | Januvia | Merck Sharp & D | $4,090,836,821 | Diabetes |
| 10 | Revlimid | Celgene/BMS | $3,859,804,789 | Blood cancers & bone marrow disease |
| 11 | Entresto | Novartis | $3,430,441,590 | Heart failure |
| 12 | Lantus Solostar | Sanofi-Aventis | $3,157,233,282 | Diabetes |
| 13 | Biktarvy | Gilead Sciences | $3,152,256,269 | HIV infection |
| 14 | Stelara* | Janssen Biotech* | $2,987,778,600 | Psoriasis, psoriatic arthritis, Crohn's disease |
| 15 | Xtandi | Astellas Pharma | $2,601,510,278 | Prostate cancer |
| 16 | Myrbetriq | Astellas Pharma | $2,510,288,600 | Overactive bladder |
| 17 | Imbruvica | Pharmacyclics, | $2,371,893,292 | Blood cancers |
| 18 | Mounjaro | Eli Lilly & Co. | $2,361,384,157 | Diabetes, weight loss |
| 19 | Enbrel Sureclick | Amgen | $2,054,858,499 | Various kind of arthritis |
| 20 | Ibrance | Pfizer US Pharm | $2,020,903,604 | Breast cancer |
| 21 | Symbicort | Astrazeneca | $2,004,295,918 | Asthma, COPD |
| 22 | Jakafi | Incyte Corporat | $1,940,765,069 | Bone marrow disorders |
| 23 | Novolog Flexpen | Novo Nordisk | $1,875,605,627 | Diabetes |
| 24 | Ofev | Boehringer Ing. | $1,837,061,150 | Pulmonary fibrosis |
| 25 | Linzess | Allergan Inc. | $1,825,245,843 | IBS, constipation |
| 26 | Invega Sustenna | Janssen Pharm. | $1,821,418,393 | Schizophrenia |
| 27 | Pomalyst | Celgene/BMS | $1,709,288,465 | Blood cancers |
| 28 | Ingrezza | Neurocrine Bios | $1,705,132,723 | Huntington’s disease |
| 29 | Lenalidomide | Amneal Pharmaceuticals / Sun Pharma / Teva Pharmaceuticals | $1,681,292,157 | Blood cancers & bone marrow disease |
| 30 | Rybelsus | Novo Nordisk | $1,665,906,943 | Diabetes, weight loss |
| 31 | Restasis | Allergan Inc. | $1,501,664,198 | Chronic dry eye |
| 32 | Creon | Abbvie US LLC | $1,466,866,603 | Pancreatic enzyme replacement |
| 33 | Arexvy | Glaxosmithkline | $1,387,933,256 | RSV prevention |
| 34 | Breo Ellipta | Glaxosmithkline | $1,373,600,714 | Asthma, COPD |
| 35 | Vyndamax | Pfizer US Pharm | $1,349,659,508 | Amyloid heart disease |
Their rise reflects both an aging population and expanding preventative treatment for stroke and atrial fibrillation.
With almost four million beneficiaries, Eliquis is prescribed to roughly one in 10 Part D enrollees.
Diabetes and Weight-Loss Therapies Surge in America
Four GLP-1 and SGLT2 diabetes drugs—Ozempic, Jardiance, Trulicity, and Farxiga—collectively totaled $29.7 billion.
Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro also double as weight-loss aids, driving demand beyond traditional type-2 diabetes patients.
This (sortable table) lists cost per dose for the top 35 drugs.
| Rank | Drug Name | Company | Generic Name | # of Beneficiaries | Medicare Spending Per Dosage Unit |
|---|---|---|---|---|---|
| 1 | Eliquis | BMS Primarycare | Apixaban | 3,927,848 | $10 |
| 2 | Ozempic | Novo Nordisk | Semaglutide | 1,464,468 | $356 |
| 3 | Jardiance | Boehringer Ing. | Empagliflozin | 1,882,768 | $20 |
| 4 | Trulicity | Eli Lilly & Co. | Dulaglutide | 938,731 | $483 |
| 5 | Xarelto | Janssen Pharm. | Rivaroxaban | 1,324,165 | $18 |
| 6 | Trelegy Ellipta | Glaxosmithkline | Fluticasone/Umeclidin/Vilanter | 1,050,583 | $11 |
| 7 | Humira(Cf) Pen | Abbvie US LLC | Adalimumab | 61,474 | $3,750 |
| 8 | Farxiga | Astrazeneca | Dapagliflozin Propanediol | 993,909 | $20 |
| 9 | Januvia | Merck Sharp & D | Sitagliptin Phosphate | 843,391 | $19 |
| 10 | Revlimid | Celgene/BMS | Lenalidomide | 36,967 | $878 |
| 11 | Entresto | Novartis | Sacubitril/Valsartan | 663,587 | $12 |
| 12 | Lantus Solostar | Sanofi-Aventis | Insulin Glargine,Hum.Rec.Anlog | 1,198,294 | $30 |
| 13 | Biktarvy | Gilead Sciences | Bictegrav/Emtricit/Tenofov Ala | 83,843 | $133 |
| 14 | Stelara* | Janssen Biotech* | Ustekinumab | 22,930 | $26,818 |
| 15 | Xtandi | Astellas Pharma | Enzalutamide | 28,658 | $146 |
| 16 | Myrbetriq | Astellas Pharma | Mirabegron | 769,978 | $15 |
| 17 | Imbruvica | Pharmacyclics, | Ibrutinib | 17,100 | $487 |
| 18 | Mounjaro | Eli Lilly & Co. | Tirzepatide | 370,203 | $540 |
| 19 | Enbrel Sureclick | Amgen | Etanercept | 34,287 | $1,812 |
| 20 | Ibrance | Pfizer US Pharm | Palbociclib | 16,015 | $753 |
| 21 | Symbicort | Astrazeneca | Budesonide/Formoterol Fumarate | 984,400 | $39 |
| 22 | Jakafi | Incyte Corporat | Ruxolitinib Phosphate | 14,041 | $298 |
| 23 | Novolog Flexpen | Novo Nordisk | Insulin Aspart | 588,526 | $39 |
| 24 | Ofev | Boehringer Ing. | Nintedanib Esylate | 20,444 | $221 |
| 25 | Linzess | Allergan Inc. | Linaclotide | 565,088 | $18 |
| 26 | Invega Sustenna | Janssen Pharm. | Paliperidone Palmitate | 70,988 | $2,344 |
| 27 | Pomalyst | Celgene/BMS | Pomalidomide | 12,739 | $1,089 |
| 28 | Ingrezza | Neurocrine Bios | Valbenazine Tosylate | 29,191 | $268 |
| 29 | Lenalidomide | Amneal Pharmaceuticals / Sun Pharma / Teva Pharmaceuticals | Lenalidomide | 20,403 | $682 |
| 30 | Rybelsus | Novo Nordisk | Semaglutide | 285,693 | $32 |
| 31 | Restasis | Allergan Inc. | Cyclosporine | 492,479 | $11 |
| 32 | Creon | Abbvie US LLC | Lipase/Protease/Amylase | 185,325 | $9 |
| 33 | Arexvy | Glaxosmithkline | Rsvpref3 Antigen/As01e/PF | 4,390,151 | $316 |
| 34 | Breo Ellipta | Glaxosmithkline | Fluticasone/Vilanterol | 556,799 | $7 |
| 35 | Vyndamax | Pfizer US Pharm | Tafamidis | 7,589 | $735 |
Their high list prices—Ozempic averages $356 per dose—illustrate how novel biologics multiply spending even with smaller patient counts.
Cancer and Autoimmune Biologics are Expensive Drugs
Revlimid, Humira, and Stelara each exceed $3 billion despite treating fewer than 100,000 beneficiaries each.
Revlimid’s $878 per dose and Stelara’s staggering $26,818 underscore why biologics dominate specialty-drug budgets.
Learn More on the Voronoi App 
Want more health-related data storytelling? Check out Ranked: Countries That Spend the Most Years in Poor Health on Voronoi, the new app from Visual Capitalist.
Popular
-
United States3 weeks agoMapped: America’s Fastest-Growing States (2025-2050)
-
Demographics2 weeks agoRanked: The World’s Oldest People in History
-
Healthcare3 weeks agoMapped: Life Expectancy Around the World in 2025
-
Economy1 week agoRanked: U.S. States With the Highest Homelessness Rates
-
Education2 weeks agoRanked: The World’s Most Educated Populations, Across 45 Countries
-
Central Banks4 weeks agoRanked: The Top 50 Countries by Central Bank Reserves
-
Economy3 weeks agoRanked: Countries With the Most High-Speed Rail in 2025
-
Automotive3 weeks agoRanked: Cars With the Best Resale Value in 2025